Trintellix vs Spravato
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Trintellix | US Spravato | |
|---|---|---|
| Generic name | vortioxetine | esketamine |
| Drug class | Serotonin Modulator (Antidepressant) | NMDA Receptor Antagonist |
| Treats | Major depressive disorder | Treatment-resistant depression |
| Category | Mental Health | Mental Health |
| Manufacturer | Takeda/Lundbeck | Janssen |
| Year approved | 2013 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $130M | — |
| Common side effects | Nausea, Sexual problems, Constipation, Vomiting | Sedation, Dissociation, Abuse and misuse potential, Increased blood pressure |
Trintellix
Frequently asked questions
Is Trintellix or Spravato better?
Neither is universally "better." Trintellix (vortioxetine) and Spravato (esketamine) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trintellix and Spravato?
Trintellix is a Serotonin Modulator (Antidepressant) made by Takeda/Lundbeck, while Spravato is a NMDA Receptor Antagonist made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trintellix has the larger estimated TV advertising budget of the two.